The Latest Analyst Ratings for CARISMA Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for CARISMA Therapeutics (NASDAQ:CARM) in the last quarter. The average price target for the stock is $11.0, which is significantly higher than its current price of $4.1. This average has increased by 10.0% from the previous average price target of $10.00.
October 03, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on CARISMA Therapeutics, with an average price target significantly higher than its current price.
The bullish ratings and higher price target suggest that analysts believe the stock has potential for significant growth. This could lead to increased investor interest and a potential increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100